What is PReCePT?
The preventing cerebral palsy in preterm labour (PReCePT) project was developed by the West of England AHSN in collaboration with University Hospitals Bristol NHS Foundation Trust to help reduce cerebral palsy in preterm babies by increasing antenatal administration of magnesium sulphate (MgSO4) to mothers in preterm labour. The cost per dose is around £1.
What the PSC did
Three midwives led the project and developed a baseline audit, training plan and delivery plan. Resources include:
- standard patient pathway guidance for the management of suspected preterm labour
- an information pack for clinicians to promote use of MgSO4 and support improved data capture on maternity unit databases
- a patient information leaflet describing when MgSO4 may be appropriate as a treatment
- a visual prompt for staff to identify patients who may benefit from being given MgSO4 as a neuroprotector.
All five maternity units in the West of England AHSN region adopted the intervention. Projection modelling indicates that since its launch in August 2014, phase one of PReCePT has prevented seven cases of cerebral palsy across the region.
Between 4,000 and 5,000 babies are born before 30 weeks’ gestation in England per year. Successful scaling up of PReCePT across England is predicted to prevent several hundred cases of cerebral palsy per year in this population.
This is one of seven projects selected for national adoption and spread across the AHSN network during 2018 to 2020, and has received scaling-up funding of £0.5 million from The Health Foundation.